Yungjin Pham (Chae J. Lee, CEO) and Genome & Company (JiSoo Pae, CEO) are starting active cooperation to search for novel drug candidates for combination treatment with cancer immunotherapy.

On October 1st, Yungjin Pharm signed a technology transfer and joint research agreement with Genome & Company , which utilize Genome&Company's unique platform technology, GENOME-IO for the development of immunotherapeutic drugs, Yungjin Pharm will pay an half million USD to Genome & Company as an upfront for using 2 targets selected by GENOME-IO.

Yungjin Pharm will acquire the right to development and commercialization of the future candidates.